Group III mGlu receptor agonist that exhibits higher potency at mGlu4 than mGlu8 (EC50 values are 49 and 124 μM respectively) with no activity at mGlu7. Selectively inhibits synaptic activity in the lateral perforant pathway (IC50 values are 130 and 1859 μM in the lateral and medial perforant pathways respectively). Conformationally restrained analog of L-AP4 (Cat No. 0103).
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 209.14. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||9.56 mL||47.81 mL||95.63 mL|
|2.5 mM||1.91 mL||9.56 mL||19.13 mL|
|5 mM||0.96 mL||4.78 mL||9.56 mL|
|25 mM||0.19 mL||0.96 mL||1.91 mL|
References are publications that support the biological activity of the product.
Crooks et al (1986) Cyclic analogues of 2-amino-4-phosphonobutanoic acid (APB) and their inhibition of hippocampal excitatory transmission and displacement of [3H]APB binding. J.Med.Chem. 29 1988 PMID: 3020251
Ayala et al (2008) Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated. Neuropharmacology 54 804 PMID: 18255102
Jones et al (2008) Metabotropic glutamate receptors mGluR4 and mGluR8 regulate transmission in the lateral olfactory tract-piriform cortex synpase. Neuropharmacology 55 440 PMID: 18625254
If you know of a relevant reference for Z-Cyclopentyl-AP4, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Z-Cyclopentyl-AP4, Z-Cyclopentyl-AP4 supplier, Group, III, mGlur, agonists, mGlu4, mGluR4, mGlu8, mGluR8, Receptors, Glutamate, Metabotropic, (Metabotropic), 3249, Tocris Bioscience
Citations for Z-Cyclopentyl-AP4
Citations are publications that use Tocris products.
Currently there are no citations for Z-Cyclopentyl-AP4. Do you know of a great paper that uses Z-Cyclopentyl-AP4 from Tocris? Please let us know.
Reviews for Z-Cyclopentyl-AP4
There are currently no reviews for this product. Be the first to review Z-Cyclopentyl-AP4 and earn rewards!
Have you used Z-Cyclopentyl-AP4?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.